Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00493870 · ClinicalTrials.gov registry record · Phase 3
TAC Versus TC for Adjuvant Breast Cancer
A Phase 3 study, sponsored by US Oncology Research.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,961
- Enrollment target
NCT00493870 is a Phase 3 study that has completed, run by US Oncology Research. The registered enrollment target is 1,961 participants.
The verdict
NCT00493870, a Phase 3 study, has completed, sponsored by US Oncology Research.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,961 participants
- Enrollment target
Study Summary
The purpose of this research study is to find out what effects (good and bad) TC or TAC has on early stage HER2- breast cancer.
Interventions
- DRUG Cyclophosphamide
- DRUG Docetaxel
- DRUG Doxorubicin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,961 participants |
| Start Date | 2007-05-29 |
| Est. Completion | 2020-03-30 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00493870
The ClinicalTrials.gov registry entry for NCT00493870 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,961 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is US Oncology Research, which has 27 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Cyclophosphamide is the first listed.
NCT00493870 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00493870 about?
NCT00493870 is a clinical study titled "TAC Versus TC for Adjuvant Breast Cancer". The purpose of this research study is to find out what effects (good and bad) TC or TAC has on early stage HER2- breast cancer.
What is the current status of trial NCT00493870?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,961 participants. The study started on 2007-05-29. Estimated completion is 2020-03-30.
What interventions are being tested in trial NCT00493870?
The interventions under investigation include: Cyclophosphamide (DRUG), Docetaxel (DRUG), Doxorubicin (DRUG).
Who is sponsoring clinical trial NCT00493870?
This trial is sponsored by US Oncology Research, which has 27 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.